Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq:…
NEOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Neogen Corporation – NEOG
NEW ORLEANS, Sept. 03, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder…
Atypical AI Debuts ExamJam SAT: Personalized Prep That Feels Like a Human Tutor
San Francisco, CA , Sept. 03, 2025 (GLOBE NEWSWIRE) -- Atypical AI…
Ai20x Launches as a Solana-Powered Experiment in Sustainable Crypto Design
Paris, France, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ai20x, a Solana-powered experiment…
Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
September 03, 2025 17:17 ET | Source: Senseonics Holdings, Inc. CGM commercial…
Sotera Health Announces Secondary Offering of Common Stock
September 03, 2025 16:57 ET | Source: Sotera Health Services, LLC CLEVELAND,…
UPDATE — vTv Therapeutics to Participate in Upcoming September Investor Conferences
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc. HIGH POINT,…
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa.,…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2025 17:00 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept.…
